- Clinical and Translational Research Collaboration Will Evaluate Multiple AlloCAR T Candidates Across the Allogene Portfolio Targeting Multiple Tumor Types
SOUTH SAN FRANCISCO, Calif. and HOUSTON, Oct. 15, 2020 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, and The University of Texas MD Anderson Cancer Center today announced a strategic five-year collaboration agreement for the preclinical and clinical investigation of AlloCAR T candidates across Allogene’s broad portfolio of hematologic and solid tumors.
“MD Anderson’s expertise in innovative clinical trials and well established translational research infrastructure will provide unique insights that will help expedite the development of AlloCAR T therapies,” said Rafael Amado, M.D., Executive Vice President of Research and Development and Chief Medical Officer of Allogene. “Coupled with Allogene’s cell therapy expertise, we believe this institution-industry alliance could play an important role in bringing this next revolution in oncology treatment to patients.”
Under the agreement, MD Anderson and Allogene will collaborate on the design and conduct of preclinical and clinical studies with oversight from a joint steering committee. Allogene will provide funding, developmental candidates, and other support. Responsibility for regulatory filings will be agreed upon by the joint steering committee.
“We share Allogene’s commitment to advancing novel therapies that will translate into effective treatments for cancer patients,” said Christopher Flowers, M.D., ad interim division head of Cancer Medicine and chair of Lymphoma and Myeloma at MD Anderson. “This collaboration will enable us to work together closely to advance allogeneic cell therapies to better address significant unmet medical needs for patients across the spectrum of oncologic diseases.”
About MD Anderson
The University of Texas MD Anderson Cancer Center in Houston ranks as one of the world's most respected centers focused on cancer patient care, research, education and prevention. The institution’s sole mission is to end cancer for patients and their families around the world. MD Anderson is one of only 51 comprehensive cancer centers designated by the National Cancer Institute (NCI). MD Anderson is ranked No.1 for cancer care in U.S. News & World Report’s “Best Hospitals” survey. It has ranked as one of the nation’s top two hospitals for cancer care since the survey began in 1990 and has ranked first 16 times in the last 19 years. MD Anderson receives a cancer center support grant from the NCI of the National Institutes of Health (P30 CA016672).
About Allogene Therapeutics
Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. Led by a management team with significant experience in cell therapy, Allogene is developing a pipeline of “off-the-shelf” CAR T cell therapy candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients. For more information, please visit www.allogene.com, and follow @AllogeneTx on Twitter and LinkedIn.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The press release may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the ability to innovate in allogeneic cell therapy and advance the preclinical or clinical development of investigational AlloCAR T therapies, and the potential benefits of AlloCAR T therapy. Various factors may cause differences between Allogene’s expectations and actual results as discussed in greater detail in Allogene’s filings with the SEC, including without limitation in its Form 10-Q for the quarter ended June 30, 2020. Any forward-looking statements that are made in this press release speak only as of the date of this press release. Allogene assumes no obligation to update the forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
AlloCAR T™ is a trademark of Allogene Therapeutics, Inc.
Allogene Media/Investor Contact:
Christine Cassiano
Chief Communications Officer
(714) 552-0326
Christine.Cassiano@allogene.com
MD Anderson Contact:
Clayton R. Boldt, Ph.D.
MD Anderson Public Relations
(713) 792-9518
crboldt@mdanderson.org
Source: Allogene Therapeutics, Inc.
